<DOC>
	<DOCNO>NCT01939665</DOCNO>
	<brief_summary>Irreversible electroporation ( IRE ) new , minimal-invasive image-guided treatment method tumor amenable surgical resection thermal ablation , due vicinity near vital structure vessel bile duct . With IRE , multiple electrical pulse apply tumorous tissue . These pulse alter exist transmembrane potential cell membrane , create 'nanopores ' , cell dy loss homeostasis . The purpose study investigate safety percutaneous IRE treatment patient locally advance pancreatic carcinoma ( LAPC ) . Other objective feasibility efficacy IRE base upon symptomatic response tumor response . Fourty patient histologically confirm locally advanced pancreatic adenocarcinoma ( &lt; 5cm ) undergo percutaneous irreversible electroporation tumor use CT ultrasound guidance . After IRE , patient carefully monitor ( serious ) adverse event register . Follow-up consist frequent CT scanning , well serum CA19.9 tumor marker . We hypothesize IRE pancreas induce good symptom palliation local tumor control , without cause severe complication .</brief_summary>
	<brief_title>PANFIRE Study : Irreversible Electroporation ( IRE ) Treat Locally Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Screening must perform longer 2 week prior study inclusion . Radiologic confirmation LAPC least ceCT chest abdomen ( upper abdomen scan accord dedicate 3mm slice multiphase pancreatic tumor protocol ) , perform maximum 2 week prior procedure ; Maximum tumor diameter ≤ 5 cm ; Histological cytological confirmation pancreatic adenocarcinoma ; Age ≥ 18 year ; ASAclassification 0 3 Life expectancy least 12 week ; Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior definite inclusion ; Hemoglobin ≥ 5.6 mmol/L ; Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; Platelet count ≥ 100*109/l ; Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; ALT AST ≤ 2.5 x ULN ; Serum creatinine ≤ 1.5 x ULN calculate creatinine clearance ≥ 50 ml/min ; Prothrombin time INR &lt; 1.5 x ULN ; Activated partial thromboplastin time &lt; 1.25 x ULN ( therapeutic anticoagulation therapy allow treatment interrupt judge treat physician ) ; Written inform consent ; Resectable pancreatic adenocarcinoma discuss multidisciplinary hepatobiliary team ; Extrapancreatic metastasis ; Successful staging ( radio ) chemotherapy previous unresectable/borderline tumor resectable tumor ; Stage IV pancreatic carcinoma ; History epilepsy ; History cardiac disease : Congestive heart failure &gt; NYHA class 2 ; Active Coronary Artery Disease ( define myocardial infarction within 6 month prior screen ) ; Cardiac arrhythmia require antiarrhythmic therapy pacemaker ( beta blocker antihypertensive regimen permit ) ; Uncontrolled hypertension . Blood pressure must ≤160/95 mmHg time screen stable antihypertensive regimen ; Compromised liver function ( e.g . sign portal hypertension , INR &gt; 1,5 without use anticoagulant , ascites ) ; Uncontrolled infection ( &gt; grade 2 NCICTC version 3.0 ) ; Pregnant breastfeeding subject . Women childbearing potential must negative pregnancy test perform within 7 day start treatment ; Immunotherapy ≤ 6 week prior procedure ; Chemotherapy ≤ 6 week prior procedure ; Radiotherapy ≤ 6 week prior procedure ; Concomitant use anticonvulsive antiarrhythmic drug ( beta blocker use antihypertensive ) ; Allergy contrast medium ; Any implant stimulation device ; Any implant metal stent/device within area ablation remove ; Any condition unstable could jeopardize safety subject compliance study ; Of note , patient contraindication MRI exclude participation : case radiologic followup consist CTscanning accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Locally advanced pancreatic carcinoma</keyword>
	<keyword>LAPC</keyword>
	<keyword>Irreversible electroporation</keyword>
	<keyword>NanoKnife</keyword>
	<keyword>IRE</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Non-thermal ablation</keyword>
	<keyword>Percutaneous ablation</keyword>
	<keyword>Low Energy Direct Current</keyword>
</DOC>